Heritage Trust Co Takes Position in Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

Heritage Trust Co purchased a new position in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH - Free Report) during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm purchased 18,350 shares of the medical equipment provider's stock, valued at approximately $1,938,000.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the stock. Geode Capital Management LLC grew its position in shares of Zimmer Biomet by 2.6% during the third quarter. Geode Capital Management LLC now owns 4,879,385 shares of the medical equipment provider's stock worth $524,942,000 after acquiring an additional 125,852 shares during the last quarter. Van ECK Associates Corp grew its position in Zimmer Biomet by 5.9% during the 4th quarter. Van ECK Associates Corp now owns 3,955,449 shares of the medical equipment provider's stock worth $417,814,000 after purchasing an additional 218,688 shares during the last quarter. Franklin Resources Inc. increased its stake in Zimmer Biomet by 398.7% in the fourth quarter. Franklin Resources Inc. now owns 3,497,764 shares of the medical equipment provider's stock valued at $369,469,000 after purchasing an additional 2,796,372 shares during the period. Norges Bank purchased a new position in shares of Zimmer Biomet during the fourth quarter worth about $216,223,000. Finally, FMR LLC lifted its position in Zimmer Biomet by 91.6% during the 4th quarter. FMR LLC now owns 1,438,011 shares of the medical equipment provider's stock worth $151,897,000 after acquiring an additional 687,675 shares during the period. 88.89% of the stock is owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other news, SVP Lori Winkler sold 1,443 shares of the firm's stock in a transaction that occurred on Wednesday, March 5th. The shares were sold at an average price of $104.40, for a total transaction of $150,649.20. Following the completion of the sale, the senior vice president now owns 8,768 shares of the company's stock, valued at $915,379.20. This trade represents a 14.13 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this link. Company insiders own 0.95% of the company's stock.

Remove Ads

Wall Street Analyst Weigh In

ZBH has been the topic of a number of analyst reports. JMP Securities restated a "market outperform" rating and issued a $140.00 price target on shares of Zimmer Biomet in a research note on Friday, February 7th. JPMorgan Chase & Co. upgraded shares of Zimmer Biomet from a "neutral" rating to an "overweight" rating and increased their price target for the company from $125.00 to $128.00 in a report on Tuesday, December 17th. Stifel Nicolaus lifted their price target on Zimmer Biomet from $130.00 to $138.00 and gave the stock a "buy" rating in a research note on Thursday, January 23rd. Barclays lowered their price objective on shares of Zimmer Biomet from $118.00 to $112.00 and set an "underweight" rating on the stock in a research note on Monday, February 10th. Finally, Truist Financial restated a "hold" rating and set a $113.00 target price (down previously from $118.00) on shares of Zimmer Biomet in a research report on Monday, February 10th. Two research analysts have rated the stock with a sell rating, eleven have issued a hold rating and nine have issued a buy rating to the company's stock. According to MarketBeat, the company currently has a consensus rating of "Hold" and a consensus target price of $124.15.

Zimmer Biomet Stock Down 0.5 %

Shares of ZBH traded down $0.51 during midday trading on Monday, hitting $101.84. The stock had a trading volume of 2,164,629 shares, compared to its average volume of 1,633,558. The company has a debt-to-equity ratio of 0.43, a current ratio of 1.91 and a quick ratio of 0.99. The firm has a market cap of $20.27 billion, a price-to-earnings ratio of 22.89, a price-to-earnings-growth ratio of 1.95 and a beta of 0.84. Zimmer Biomet Holdings, Inc. has a twelve month low of $97.69 and a twelve month high of $127.32. The company has a 50 day simple moving average of $106.31 and a two-hundred day simple moving average of $107.03.

Zimmer Biomet (NYSE:ZBH - Get Free Report) last announced its quarterly earnings data on Thursday, February 6th. The medical equipment provider reported $2.31 earnings per share for the quarter, beating the consensus estimate of $2.30 by $0.01. Zimmer Biomet had a return on equity of 12.99% and a net margin of 11.77%. During the same period in the previous year, the business posted $2.20 earnings per share. On average, analysts anticipate that Zimmer Biomet Holdings, Inc. will post 8.22 EPS for the current year.

Zimmer Biomet Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, April 30th. Investors of record on Monday, March 31st will be issued a $0.24 dividend. The ex-dividend date is Monday, March 31st. This represents a $0.96 dividend on an annualized basis and a yield of 0.94%. Zimmer Biomet's payout ratio is 21.57%.

Zimmer Biomet Company Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.